A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
This study is testing if adding a chemotherapy medicine called docetaxel to standard hormone treatments can better slow down the growth of prostate cancer. Researchers want to see if this combined approach works better than the usual treatments alone for patients who still have elevated PSA levels.
You might be able to join if you have prostate cancer that has spread to other parts of the body and your PSA levels remain at 2.0 or higher after starting hormone therapy. Participants must not have prior treatment with certain types of chemotherapy or moderate to severe nerve damage in their hands and feet.
Participants will receive either the standard hormone therapy alone or hormone therapy combined with the chemotherapy drug docetaxel. Your health and cancer response will be closely monitored by the study doctors throughout the process.
This study is currently recruiting patients and takes place in locations including Anchorage, Alaska in the United States.
- 1Testing if adding chemotherapy to hormone therapy improves prostate cancer treatment
- 2Open to patients whose cancer has spread and who have a suboptimal PSA response
- 3Currently recruiting participants at select locations
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.